PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31460017-5 2019 A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44. Paclitaxel 12-15 CD44 molecule (Indian blood group) Homo sapiens 99-103 33692661-7 2020 Due to vascular and stromal contributions, differences in the response of vascularized tumors to Taxol (shrinkage and CD44 expression) are apparent compared with simpler models. Paclitaxel 97-102 CD44 molecule (Indian blood group) Homo sapiens 118-122 33050539-8 2020 We also demonstrated that breast cancer patients treated with paclitaxel chemotherapy exhibited increased CD44-expressing TMPs. Paclitaxel 62-72 CD44 molecule (Indian blood group) Homo sapiens 106-110 31867270-10 2019 In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1). Paclitaxel 38-48 CD44 molecule (Indian blood group) Homo sapiens 194-198 34004196-5 2021 Functionalized with the outer CS shell, TLA/PTX@CS entered MDR breast cancer (MCF-7/MDR) cells via CD44 receptor-mediated endocytosis. Paclitaxel 44-47 CD44 molecule (Indian blood group) Homo sapiens 99-103 32779438-12 2020 Overexpression of GATA5 was not only alone but also synergized with Paclitaxel to inhibit expression of CD44 and CD133 in Bel7402 or PLC/PRF/5 cells. Paclitaxel 68-78 CD44 molecule (Indian blood group) Homo sapiens 104-108 31460017-5 2019 A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44. Paclitaxel 12-15 CD44 molecule (Indian blood group) Homo sapiens 173-177 31460017-5 2019 A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44. Paclitaxel 64-67 CD44 molecule (Indian blood group) Homo sapiens 99-103 30112929-3 2018 Herein, we report a novel dual-functional paclitaxel (PTX) liposome system possessing both CD44-targeting and mitochondrial-targeting properties to enhance drug accumulation in mitochondria and trigger apoptosis of drug-resistant cancer cells. Paclitaxel 42-52 CD44 molecule (Indian blood group) Homo sapiens 91-95 30818864-0 2019 Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. Paclitaxel 99-109 CD44 molecule (Indian blood group) Homo sapiens 46-50 30112929-3 2018 Herein, we report a novel dual-functional paclitaxel (PTX) liposome system possessing both CD44-targeting and mitochondrial-targeting properties to enhance drug accumulation in mitochondria and trigger apoptosis of drug-resistant cancer cells. Paclitaxel 54-57 CD44 molecule (Indian blood group) Homo sapiens 91-95 29027133-0 2017 Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment. Paclitaxel 43-53 CD44 molecule (Indian blood group) Homo sapiens 57-61 30115698-0 2018 CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. Paclitaxel 48-58 CD44 molecule (Indian blood group) Homo sapiens 0-4 30179299-0 2018 Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells. Paclitaxel 47-57 CD44 molecule (Indian blood group) Homo sapiens 88-92 30179299-7 2018 Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERalpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription. Paclitaxel 28-38 CD44 molecule (Indian blood group) Homo sapiens 179-183 30179299-7 2018 Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERalpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription. Paclitaxel 135-145 CD44 molecule (Indian blood group) Homo sapiens 179-183 29027133-2 2017 We developed a hybrid nanocarrier for the CD44-targeted delivery of ibuprofen (IBU) and paclitaxel (PTX). Paclitaxel 88-98 CD44 molecule (Indian blood group) Homo sapiens 42-46 29027133-2 2017 We developed a hybrid nanocarrier for the CD44-targeted delivery of ibuprofen (IBU) and paclitaxel (PTX). Paclitaxel 100-103 CD44 molecule (Indian blood group) Homo sapiens 42-46 27842858-2 2017 In addition, through modifying by tLyP-1, the anticancer scope of tLyP-1-HA-PTX conjugate was expanded from tumor cells expressing CD44 receptors to those of expressing NRP1 receptors. Paclitaxel 76-79 CD44 molecule (Indian blood group) Homo sapiens 131-135 32264281-0 2017 Correction: Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy. Paclitaxel 89-99 CD44 molecule (Indian blood group) Homo sapiens 29-33 32264281-1 2017 Correction for "Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy" by Dayeon Yun et al., J. Paclitaxel 93-103 CD44 molecule (Indian blood group) Homo sapiens 33-37 28523716-6 2017 We found that CD44+ Fbs promoted breast cancer cell survival and paclitaxel resistance and inhibited paclitaxel-induced apoptosis. Paclitaxel 65-75 CD44 molecule (Indian blood group) Homo sapiens 14-18 28523716-6 2017 We found that CD44+ Fbs promoted breast cancer cell survival and paclitaxel resistance and inhibited paclitaxel-induced apoptosis. Paclitaxel 101-111 CD44 molecule (Indian blood group) Homo sapiens 14-18 32264448-0 2017 Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy. Paclitaxel 77-87 CD44 molecule (Indian blood group) Homo sapiens 17-21 27842858-5 2017 The tLyP-1-HA-PTX conjugate was especially endowed with efficient cell-penetrating and tumor NRP1 receptor targeting ability and compensate for the decreasing of uptake caused by suppression of CD44 receptor, which is more significant when NRP1 receptor is highly expressed. Paclitaxel 14-17 CD44 molecule (Indian blood group) Homo sapiens 194-198 27796093-1 2016 A novel CD44 receptor targeting and endosome pH-sensitive dual functional hyaluronic acid-deoxycholic acid-histidine (HA-DOCA-His) micellar system was designed for intracellular paclitaxel (PTX) delivery. Paclitaxel 178-188 CD44 molecule (Indian blood group) Homo sapiens 8-12 27796093-1 2016 A novel CD44 receptor targeting and endosome pH-sensitive dual functional hyaluronic acid-deoxycholic acid-histidine (HA-DOCA-His) micellar system was designed for intracellular paclitaxel (PTX) delivery. Paclitaxel 190-193 CD44 molecule (Indian blood group) Homo sapiens 8-12 27462592-10 2016 And growth inhibition of OVCAR3 CD44(+)CD117(+) cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Paclitaxel 57-67 CD44 molecule (Indian blood group) Homo sapiens 32-36 27045981-0 2016 CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Paclitaxel 140-150 CD44 molecule (Indian blood group) Homo sapiens 0-4 27045981-13 2016 Combination of HA coated SLM nanoparticles and PTX nanoparticles showed the highest cytotoxicity against CD44(+) cells. Paclitaxel 47-50 CD44 molecule (Indian blood group) Homo sapiens 105-109 27305935-8 2016 Notably, paclitaxel-loaded HA-PLGA NPs (PTX-HA-PLGA NPs) exhibited better antitumor effects in CD44-positive MCF-7 breast tumor cells than Taxol (a clinical paclitaxel formulation). Paclitaxel 9-19 CD44 molecule (Indian blood group) Homo sapiens 95-99 27462592-12 2016 Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44(+)CD117(+) cells. Paclitaxel 32-42 CD44 molecule (Indian blood group) Homo sapiens 100-104 27255186-5 2016 Bel 7402 cell resistance to paclitaxel was associated with the expression of the "stemness" markers CD44 and CD133. Paclitaxel 28-38 CD44 molecule (Indian blood group) Homo sapiens 100-104 26300335-13 2015 Based on a series of in vitro and in vivo experiments, HA-ss-PTX performed well in drug loading, cellular internalization, tumor targeting by entering tumor cells via CD44-caveolae-mediated endocytosis and rapidly release drug at target in the presence of GSH. Paclitaxel 61-64 CD44 molecule (Indian blood group) Homo sapiens 167-171 26851390-0 2016 Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Paclitaxel 41-51 CD44 molecule (Indian blood group) Homo sapiens 98-102 26462028-4 2015 Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2). Paclitaxel 107-117 CD44 molecule (Indian blood group) Homo sapiens 236-240 25890771-0 2015 Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer. Paclitaxel 15-25 CD44 molecule (Indian blood group) Homo sapiens 46-50 26117979-5 2015 Overexpression of CD44, observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel, doxorubicin, camptothecin or cisplatin) to cancer cells. Paclitaxel 133-143 CD44 molecule (Indian blood group) Homo sapiens 18-22 23792807-6 2013 Efficacy of targeting was shown on CD44 positive cells in the SUM159 breast cancer cell line by incubating the cells sequentially with a biotinylated anti-CD44 antibody, StA and the biotinylated nanospheres encapsulating PTX. Paclitaxel 221-224 CD44 molecule (Indian blood group) Homo sapiens 35-39 23681900-8 2014 However, when the MCF7/Adr cells transfected with CD44 siRNA were incubated with 10 times the peak plasma concentration (PPC) of taxol, their invasive ability was again enhanced. Paclitaxel 129-134 CD44 molecule (Indian blood group) Homo sapiens 50-54 24036854-3 2013 We hypothesize that a developed cancer-targeted delivery system that combines CD44 siRNA with paclitaxel would successfully deliver its payload inside cancer cells, effectively induce cell death, and prevent metastases. Paclitaxel 94-104 CD44 molecule (Indian blood group) Homo sapiens 78-82 24002934-3 2013 Therefore to improve efficacy, we have developed an ultra-small hyaluronic acid (HA) paclitaxel nanoconjugate (~5 kDa) that can passively diffuse across the leaky blood-tumor barrier and then be taken up into cancer cells (MDA-MB-231Br) via CD44 receptor-mediated endocytocis. Paclitaxel 85-95 CD44 molecule (Indian blood group) Homo sapiens 241-245 23624503-8 2013 The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity. Paclitaxel 48-58 CD44 molecule (Indian blood group) Homo sapiens 19-23 22341413-6 2013 RESULTS: The paclitaxel-hyaluronan bioconjugate bound to UC tumor cells entered intracellular compartments through a saturable and energy-dependent mechanism that involved CD44, as assessed by blocking with specific antibody. Paclitaxel 13-23 CD44 molecule (Indian blood group) Homo sapiens 172-176 23108794-6 2013 There were no significant differences in radiosensitivity or cisplatin sensitivity of stem or non-stem cells, but CD44-isolated stem cells were more resistant to paclitaxel. Paclitaxel 162-172 CD44 molecule (Indian blood group) Homo sapiens 114-118 23500524-5 2013 In this study, we confirmed that paclitaxel enriched breast CSCs (CD44+/CD24-) in a dose-dependent manner in MCF-7 human breast cancer cell line. Paclitaxel 33-43 CD44 molecule (Indian blood group) Homo sapiens 66-70 23500524-9 2013 Paclitaxel decreased CD44+/CD24- cell population in MCF-7 cells and reduced the size and number of primary mammospheres after down-regulating the Notch1. Paclitaxel 0-10 CD44 molecule (Indian blood group) Homo sapiens 21-25 23624503-3 2013 METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells). Paclitaxel 60-70 CD44 molecule (Indian blood group) Homo sapiens 74-78 23624503-3 2013 METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells). Paclitaxel 60-70 CD44 molecule (Indian blood group) Homo sapiens 132-136 23624503-3 2013 METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells). Paclitaxel 60-70 CD44 molecule (Indian blood group) Homo sapiens 132-136 23624503-3 2013 METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells). Paclitaxel 60-70 CD44 molecule (Indian blood group) Homo sapiens 132-136 23624503-6 2013 The isolated CD44(+)CD24(+)Cdx1(+) cells showed higher resistance to paclitaxel-induced cytotoxicity than CD44(+)CD24(+)p53wt cells. Paclitaxel 69-79 CD44 molecule (Indian blood group) Homo sapiens 13-17 23624503-7 2013 The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I. Paclitaxel 49-59 CD44 molecule (Indian blood group) Homo sapiens 18-22 23624503-9 2013 Silencing of Cdx1 expression and treatment with lysosomal inhibitor bafilomycin A increased paclitaxel-induced cytotoxicity in CD44(+)CD24(+)Cdx1(+) cells. Paclitaxel 92-102 CD44 molecule (Indian blood group) Homo sapiens 127-131 22309939-15 2012 Finally, whereas paclitaxel, doxorubicin, and 5-fluorouracil enriched the CD44high/CD24-/low population compared with control in SUM149, subsequent treatment with BI 2536 killed the emergent population, suggesting that it could potentially be used to prevent relapse. Paclitaxel 17-27 CD44 molecule (Indian blood group) Homo sapiens 74-78 22581025-5 2012 CD44+/CD133+ EC-CICs were also more resistant to growth inhibition induced by the chemotherapeutic drugs cisplatin and paclitaxel. Paclitaxel 143-153 CD44 molecule (Indian blood group) Homo sapiens 0-4 22350800-0 2012 Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Paclitaxel 61-71 CD44 molecule (Indian blood group) Homo sapiens 75-79 22350800-1 2012 PURPOSE: To evaluate the effect of the size of low molecular weight hyaluronan (LMW-HA) oligomers on the targeting ability of the HA-containing copolymers to the CD44-overexpressing cells for delivering Paclitaxel (PTX) to ovarian cancer. Paclitaxel 203-213 CD44 molecule (Indian blood group) Homo sapiens 162-166 22350800-7 2012 The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX). Paclitaxel 31-34 CD44 molecule (Indian blood group) Homo sapiens 109-113 22350800-7 2012 The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX). Paclitaxel 57-60 CD44 molecule (Indian blood group) Homo sapiens 109-113 22350800-7 2012 The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX). Paclitaxel 57-60 CD44 molecule (Indian blood group) Homo sapiens 109-113 22350800-8 2012 CONCLUSIONS: P-(HA)(34)-PTX was significantly more toxic than the non-targeted P-PTX in cells expressing high levels of CD44. Paclitaxel 24-27 CD44 molecule (Indian blood group) Homo sapiens 120-124 23368632-5 2013 Effect of paclitaxel on the CD44+CD117+cell viability indicated that fewer cells underwent apoptosis in 3D culture than that in 2D one. Paclitaxel 10-20 CD44 molecule (Indian blood group) Homo sapiens 28-32 21935404-11 2011 Our results thus reveal that 1) not all DTCs are necessarily CSCs; 2) conventional chemotherapeutic drugs such as taxol and etoposide may directly target CD44(+) tumor-initiating cells; and 3) DTCs generated via chronic drug selection involve epigenetic mechanisms. Paclitaxel 114-119 CD44 molecule (Indian blood group) Homo sapiens 154-158 21196304-3 2011 In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin. Paclitaxel 163-173 CD44 molecule (Indian blood group) Homo sapiens 40-44 21196304-3 2011 In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin. Paclitaxel 373-383 CD44 molecule (Indian blood group) Homo sapiens 40-44 20549538-6 2010 In vitro experiments verified that CD44(+)CD24- cells were markedly resistant to carboplatin and paclitaxol. Paclitaxel 97-107 CD44 molecule (Indian blood group) Homo sapiens 35-39 20332234-11 2010 Here, we show that paclitaxel induces P-YB-1(S102) expression, nuclear localization of activated YB-1, and CD44 expression. Paclitaxel 19-29 CD44 molecule (Indian blood group) Homo sapiens 107-111 20428807-0 2010 Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Paclitaxel 77-82 CD44 molecule (Indian blood group) Homo sapiens 54-58 20332234-13 2010 Importantly, targeting YB-1 sensitized the CD44(High)/CD24(Low) cells to paclitaxel. Paclitaxel 73-83 CD44 molecule (Indian blood group) Homo sapiens 43-47 18771959-6 2008 Importantly, the inhibitory function of Treg was significantly impaired, while the production of Th1 cytokines IFN-gamma and IL-2 and the expression of the activation marker CD44 among CD4(+) and CD8(+) T cells were augmented after paclitaxel treatment. Paclitaxel 232-242 CD44 molecule (Indian blood group) Homo sapiens 174-178 19823672-4 2009 Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. Paclitaxel 53-63 CD44 molecule (Indian blood group) Homo sapiens 258-262 19823672-4 2009 Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. Paclitaxel 53-63 CD44 molecule (Indian blood group) Homo sapiens 282-286 19823672-7 2009 Additionally, NSC23925 increases the intracellular accumulation of Pgp1 substrates: calcein AM, Rhodamine-123, paclitaxel, mitoxantrone, and doxorubicin. Paclitaxel 111-121 CD44 molecule (Indian blood group) Homo sapiens 67-71 18828019-3 2009 METHODS: We evaluate the association between expression of Pgp1, MRP1, and BCRP proteins and ET-743 or PM00104 resistance in a large panel of multi-drug resistant cell lines derived from histologically unrelated human tumors that were selected with paclitaxel, doxorubicin, cisplatin, mitoxantrane, or gemcitibine. Paclitaxel 249-259 CD44 molecule (Indian blood group) Homo sapiens 59-63 19772851-6 2009 Furthermore, down-regulation of P-gp1 led to increased sensitivity of CH(R)C5 cells to paclitaxel and doxorubicin, but not to cis-platinum, due to inhibition of P-gp1 drug efflux pump. Paclitaxel 87-97 CD44 molecule (Indian blood group) Homo sapiens 32-37 19772851-6 2009 Furthermore, down-regulation of P-gp1 led to increased sensitivity of CH(R)C5 cells to paclitaxel and doxorubicin, but not to cis-platinum, due to inhibition of P-gp1 drug efflux pump. Paclitaxel 87-97 CD44 molecule (Indian blood group) Homo sapiens 161-166 18441325-6 2008 Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Paclitaxel 179-189 CD44 molecule (Indian blood group) Homo sapiens 33-37 18441325-6 2008 Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Paclitaxel 191-196 CD44 molecule (Indian blood group) Homo sapiens 33-37 17603630-2 2007 To develop tumor-targeted drugs, we have initially evaluated whether the CD44 ligand hyaluronic acid (HA) could serve as a backbone for paclitaxel (TXL) prodrugs. Paclitaxel 136-146 CD44 molecule (Indian blood group) Homo sapiens 73-77 34752986-0 2022 CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery. Paclitaxel 33-43 CD44 molecule (Indian blood group) Homo sapiens 0-4 34752986-2 2022 In this study we evaluated the potential of an indocyanine green (ICG) and paclitaxel (PTX) loaded human serum albumin (HSA) nanoparticles that was conjugated with hyaluronic acid for use in image-guided drug delivery targeted to CD44-positive non-small cell lung cancer (NSCLC). Paclitaxel 75-85 CD44 molecule (Indian blood group) Homo sapiens 230-234 34752986-2 2022 In this study we evaluated the potential of an indocyanine green (ICG) and paclitaxel (PTX) loaded human serum albumin (HSA) nanoparticles that was conjugated with hyaluronic acid for use in image-guided drug delivery targeted to CD44-positive non-small cell lung cancer (NSCLC). Paclitaxel 87-90 CD44 molecule (Indian blood group) Homo sapiens 230-234 34278466-0 2021 Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer. Paclitaxel 29-39 CD44 molecule (Indian blood group) Homo sapiens 54-58 34278466-2 2021 The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer. Paclitaxel 107-117 CD44 molecule (Indian blood group) Homo sapiens 140-144 34278466-2 2021 The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer. Paclitaxel 119-122 CD44 molecule (Indian blood group) Homo sapiens 140-144 35595817-5 2022 Low VSNL1 and CD44 expression predicted the benefit of sequential paclitaxel treatment for all three endpoints. Paclitaxel 66-76 CD44 molecule (Indian blood group) Homo sapiens 14-18 35595817-7 2022 This is the first study to identify VSNL1 and CD44 RNA expression levels as biomarkers for selecting GC patients that are likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy. Paclitaxel 156-166 CD44 molecule (Indian blood group) Homo sapiens 46-50 33798550-11 2021 Using a xenograft model, we showed that miR-98 overexpression reversed paclitaxel resistance to CD44+ GCSCs. Paclitaxel 71-81 CD44 molecule (Indian blood group) Homo sapiens 96-100 34803458-2 2021 Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel. Paclitaxel 321-331 CD44 molecule (Indian blood group) Homo sapiens 284-288